although
tumorassoci
abnorm
glycosyl
recogn
decad
inform
regard
host
recognit
evolv
tumor
glycom
remain
elus
report
carbohydr
microarray
analysi
number
tumorassoci
carbohydr
serum
antibodi
reactiv
potenti
immunogen
human
precursor
core
intern
sequenc
nglycan
usual
mask
sugar
moieti
belong
class
glycoantigen
normal
cryptic
howev
viral
express
carbohydr
may
trigger
host
immun
respons
exampl
sarscov
display
cluster
trior
multiantennari
type
ii
chain
trimii
respect
viral
neutral
antibodi
often
target
sugar
moieti
ask
therefor
whether
prostat
tumor
express
correspond
carbohydr
trigger
antibodi
respons
vivo
use
carbohydr
microarray
analyz
panel
human
sera
includ
sampl
prostat
cancer
patient
men
benign
prostat
hyperplasia
bph
observ
igg
antibodi
target
trimiiautoantigen
readili
detect
sera
men
bph
well
cancer
importantli
antibodi
activ
select
increas
prostat
cancer
patient
thu
human
immun
system
activ
recogn
nglycan
cryptic
carbohydr
produc
target
antibodi
find
shad
light
class
previous
less
studi
immunolog
target
human
cancer
identifi
diagnost
prognost
therapeut
valu
target
requir
investig
recognit
tumorassoci
abnorm
glycosyl
rais
great
interest
potenti
carbohydratebas
cancer
biomark
prostat
cancer
pca
number
tumorassoci
aberr
carbohydr
identifi
character
includ
glycoisoform
psa
sulfat
glycolipid
blood
group
antigen
precursor
latter
repres
divers
panel
oglycan
includ
limit
antigen
tn
sialyl
globoh
branch
linear
type
ii
backbon
region
antigen
difucosyl
le
monofucosyl
monosialyl
compound
sialyl
x
blood
group
h
le
b
type
backbonebas
sialyl
sialyl
x
associ
metastat
pca
carbohydr
research
explor
divers
tumor
glycom
investig
turn
attent
immunolog
properti
tumorassoci
carbohydr
wandal
et
al
develop
oglycopeptid
microarray
monitor
human
autoantibodi
respons
tumor
antigen
success
use
detect
cancerassoci
igg
autoantibodi
differ
aberr
oglycopeptid
epitop
deriv
sera
breast
ovarian
prostat
cancer
patient
last
year
blixt
et
al
report
presenc
level
autoantibodi
significantli
higher
sera
cancer
patient
compar
sera
control
subject
highli
signific
correl
age
observ
high
level
subset
autoantibodi
glycoform
respect
significantli
associ
reduc
incid
increas
time
metastasi
result
suggest
autoantibodi
aberrantli
glycosyl
earli
stage
breast
cancer
associ
better
prognosi
padlerkaravani
et
al
found
human
carcinoma
metabol
incorpor
dietari
nonhuman
sialic
acid
monosaccharid
differ
human
sialic
acid
nacetylneuramin
acid
one
oxygen
atom
abl
trigger
differenti
antibodi
respons
use
novel
sialoglycan
microarray
present
multipl
control
investig
found
antibodi
gcstn
promin
patient
carcinoma
patient
diseas
thu
xenoautoantibodi
xenoautoantigen
consid
potenti
target
diagnost
prognost
therapeut
applic
human
carcinoma
laboratori
investig
class
cryptic
glycan
marker
differenti
express
among
differ
gleason
grade
pca
metastat
tumor
marker
includ
highmannos
cluster
triantennari
type
ii
multival
type
ii
trimii
chain
agalactosyl
deriv
trimgn
glcnac
glycoepitop
illustr
figur
share
nglycan
mancor
differ
termin
sugar
moieti
unlik
fulli
glycosyl
cellular
nglycan
often
cap
target
expos
intern
sequenc
normal
cryptic
immun
system
howev
viral
pathogen
express
carbohydr
surfac
virion
exampl
envelop
glycoprotein
heavili
coat
cluster
spike
protein
sarscov
express
trimii
moieti
importantli
viral
neutral
antibodi
often
target
carbohydr
one
open
question
whether
host
immun
system
recogn
respond
tumorexpress
nglycan
cryptic
carbohydr
newsomdavi
wang
et
al
recent
report
tumor
cellbas
vaccin
elicit
antibodi
experi
fasligandtransfect
melanoma
cell
use
anim
immun
flow
cytometri
analysi
reveal
monoclon
antibodi
mab
establish
immun
strategi
illustr
uniqu
bind
profil
bind
cell
surfac
untransform
normal
cell
strongli
bind
number
murin
human
tumor
cell
line
includ
melanoma
prostat
breast
ovarian
cancer
carbohydr
microarray
analysi
reveal
recogn
oligomannosyl
epitop
present
two
cluster
nkeyhol
limpet
hemocyanin
klh
nklh
construct
investig
neutral
epitop
recogn
human
mab
find
promot
us
investig
whether
human
immun
system
recogn
respond
tumorassoci
cryptic
glycoantigen
current
studi
character
panel
sera
men
pca
sera
men
bph
use
carbohydr
microarray
rational
tumor
carbohydr
immunogen
vivo
cancer
patient
would
possibl
mount
antibodi
respons
correspond
target
detect
antibodi
pca
subject
carbohydr
microarray
would
provid
evid
pin
specif
immunolog
target
result
studi
summar
report
panel
bank
human
sera
specimen
analysi
studi
kindli
provid
dr
zeqi
joe
zhou
egenix
inc
millbrook
ny
diagnosi
pca
bph
base
result
prostat
needl
biopsi
clinic
surgic
gleason
grade
inform
howev
avail
cohort
specimen
blind
conduct
analysi
antihuman
igg
use
carbohydr
microarray
assay
purchas
sigma
st
loui
mo
carbohydr
antigen
glycoconjug
antigen
prepar
appli
studi
list
supplementari
tabl
microarray
use
compris
distinct
antigen
prepar
includ
potenti
autoantigen
common
environment
antigen
latter
select
often
detect
signific
anticarbohydr
antibodi
human
circul
provid
control
probe
monitor
global
antibodi
profil
given
subject
member
nglycan
cryptic
sugar
moieti
illustr
figur
includ
mancor
trimgn
trimii
present
panel
spot
carbohydr
antigen
includ
nativ
human
glycoprotein
asor
agor
well
two
synthet
highmannos
cluster
nklh
nklh
microarray
print
polysaccharid
glycoprotein
dissolv
salin
lipid
prepar
liposom
describ
antigen
solut
liposom
suspens
spot
onto
nitrocelluloseco
fast
slide
schleicher
schuell
highprecis
robot
design
produc
cdna
microarray
cartesian
technolog
pixsi
immedi
use
print
microarray
slide
wash
room
temperatur
rt
min
block
bsapb
rt
min
incub
sera
rt
hour
wash
incub
titrat
secondari
antihuman
igg
antibodi
coupl
rt
min
stain
slide
rins
five
time
airdri
rt
scan
microarray
scanner
perkinelm
life
scienc
use
scan
stain
microarray
fluoresc
signal
fluoresc
intens
valu
array
spot
background
calcul
use
scanarray
express
softwar
perkinelm
life
scienc
carbohydr
array
dataset
microarray
assay
includ
sera
pca
patient
bph
patient
standard
statist
analyz
use
jmp
genom
softwar
packag
sa
institut
cari
north
carolina
standard
antibodi
reactiv
igg
shown
microarray
score
transform
medianbackground
valu
normal
set
interquartil
rang
iqr
ident
oneway
anova
perform
compar
result
obtain
among
group
andor
subgroup
student
test
appli
calcul
signific
differ
among
compar
group
first
step
carbohydr
microarray
analysi
character
global
antibodi
profil
subject
profil
measur
rel
serum
antibodi
reactiv
igg
score
divers
panel
antigen
spot
carbohydr
microarray
figur
statist
analys
follow
identifi
glycan
marker
detect
signific
level
autoantibodi
human
circul
figur
captur
pcaassoci
autoantibodi
signatur
figur
figur
antibodi
profil
illustr
overlay
plot
igg
score
yaxi
antigen
probe
align
xaxi
color
symbol
repres
igg
score
given
antibodi
specif
detect
sera
sampl
antiselfantibodi
activ
includ
anticarbohydr
antilipid
plot
left
dash
line
antinonselfantibodi
mainli
antimicrobi
polysaccharid
plot
right
line
although
sera
bph
pca
subject
illustr
gener
similar
global
antibodi
profil
antibodi
reactiv
target
cluster
spike
pca
sera
figur
figur
examin
statist
signific
detect
autoantibodi
microarray
assay
figur
dot
repres
mean
valu
triplic
array
detect
sampl
mean
given
group
subject
repres
green
bar
standard
deviat
shown
green
diamond
around
mean
valu
shown
describ
size
differ
relat
distribut
valu
group
comparison
circl
student
ttest
appear
right
diamond
intersect
circl
illustr
signific
differ
circl
intersect
less
signific
differ
vice
versa
figur
address
whether
given
autoantigen
detect
antibodi
human
sera
oneway
analysi
perform
examin
signific
differ
igg
score
among
pair
antigen
exampl
examin
pair
oragor
orasor
agorasor
respect
asor
agor
ident
protein
compon
differ
glycoepitop
express
agor
asor
display
trimgn
trimii
respect
surfacedisplay
either
two
glycoepitop
thu
pairwis
comparison
suffici
reveal
carbohydratespecif
bind
signal
shown
figur
detect
measur
antibodi
contrast
asialo
form
asor
trimii
agalato
form
agor
trimgn
captur
highli
signific
amount
igg
antibodi
figur
show
oneway
analysi
among
klh
antigen
share
klh
carrier
differ
carbohydr
unit
display
differ
cluster
configur
compar
antibodi
captur
conjug
klh
control
determin
two
cluster
detect
highli
signific
amount
igg
antibodi
pca
bph
group
figur
examin
whether
detect
serum
autoantibodi
differ
significantli
pca
bph
group
order
identifi
potenti
signatur
pca
purpos
autoantibodi
detect
pca
group
compar
detect
bph
group
two
cluster
detect
significantli
increas
level
autoantibodi
pca
group
figur
appear
effect
captur
serum
igg
agor
asor
detect
significantli
differ
level
igg
pca
bph
group
howev
wide
distribut
igg
asor
score
among
sampl
pca
patient
observ
signific
proport
sampl
produc
elev
level
igg
asor
figur
studi
examin
panel
tumorassoci
cryptic
carbohydr
antigen
potenti
immunogen
activ
human
interest
identifi
carbohydr
abl
trigger
anticarbohydr
antibodi
respons
vivo
assumpt
tumor
carbohydr
immunolog
properti
suitabl
develop
tumor
immunoassay
target
immunotherapi
repertoir
human
serum
antibodi
broad
divers
standard
microarray
dataset
antibodi
profil
differ
subject
quantit
measur
meaning
compar
technic
challeng
studi
introduc
concept
rel
antibodi
reactiv
rar
standard
global
antibodi
profil
way
antibodi
profil
comparison
independ
serum
antibodi
concentr
often
subject
influenc
subject
physiolog
patholog
statu
blood
drawn
clinic
figur
present
rar
profil
captur
test
sera
sampl
includ
pca
patient
figur
bph
subject
figur
visual
inspect
figur
readili
reveal
global
pattern
antigenspecif
antibodi
impress
similar
across
subject
bph
pca
group
howev
spike
autoantibodi
activ
emerg
background
conserv
global
antibodi
profil
interestingli
number
spike
identifi
antigen
id
locat
pcaand
bphplot
antigen
id
cardiolipin
respect
base
observ
infer
preexist
autoantibodi
contribut
enhanc
antibodi
respons
tumor
carbohydr
investig
requir
determin
whether
autoantibodi
produc
pca
patient
especi
aggress
pca
carri
specif
molecular
signatur
select
use
germlin
gene
hypermut
igv
region
practic
approach
address
issu
includ
establish
immobil
human
b
cell
clone
determin
igv
region
sequenc
clone
sequenc
singl
antibodyposit
b
cell
approach
support
recoveri
origin
pair
v
h
v
l
segment
essenti
examin
clonal
relationship
among
cell
differ
bind
affin
without
somat
mutat
background
rarstandard
global
antibodi
profil
examin
statist
meaning
detect
autoantibodi
human
circul
effort
exploratori
sinc
hit
immunolog
paradigm
regard
human
immun
recognit
selfcarbohydr
antigen
figur
show
oneway
analysi
igg
score
associ
asor
agor
abund
human
serum
glycoprotein
also
known
glycoprotein
expect
assay
detect
antibodi
fulli
glycosyl
nativ
human
serum
protein
contrast
carbohydr
microarray
detect
signific
level
antiasor
igg
asor
antiagor
igg
agor
antibodi
sera
bph
pca
patient
sinc
asor
agor
ident
protein
compon
differenti
antibodi
activ
associ
reflect
glycanbind
specif
illustr
figur
correspond
cryptic
moieti
mark
sugar
moieti
thu
igg
asor
captur
asor
predominantli
trimiispecif
igg
agor
detect
agor
reflect
bind
trimgn
detect
igg
asor
human
circul
particularli
interest
sinc
target
carbohydr
trimii
character
branch
type
ii
chain
hyperexpress
branch
type
ii
chain
determin
phal
stain
found
number
human
cancer
tissueexpress
marker
also
confirm
major
pca
view
figur
notic
signific
number
dot
igg
asor
pca
group
locat
upper
confid
limit
line
bph
group
indic
group
mean
pca
bph
differ
significantli
subset
pca
patient
produc
significantli
increas
level
igg
asor
compar
bph
group
igg
asor
specif
also
found
sarscov
neutral
antibodi
would
highli
interest
sarscov
neutral
antibodi
bind
effect
kill
trimiiposit
tumor
cell
figur
show
two
cluster
captur
substanti
increas
level
igg
compar
detect
common
klh
carrier
molecul
nklh
preserv
well
recogn
nklh
poorli
reactiv
highli
reactiv
antitumor
mab
sinc
igg
score
associ
significantli
higher
igg
score
igg
detect
human
sera
like
domin
antibodi
figur
illustr
detect
significantli
increas
amount
igg
antibodi
sera
pca
group
compar
sera
bph
group
conjug
effect
one
captur
serum
igg
among
autoantigen
examin
microarray
analysi
context
tumor
cellsurfac
express
intens
express
oligomannos
higher
gleason
grade
cancer
igg
appear
attract
serum
biomark
investig
summari
found
studi
autoantibodi
target
trimiiglycoantigen
readili
detect
human
sera
antibodi
reactiv
select
increas
pca
subject
extend
analysi
larger
cohort
pca
bph
subject
clearli
requir
determin
diagnost
prognost
valu
autoantibodi
howev
current
studi
suffici
demonstr
human
immun
system
activ
recogn
trimiiexpress
autoantigen
produc
target
antibodi
sinc
carbohydr
moieti
gener
cryptic
becom
highli
express
surfaceexpos
number
tumor
worthwhil
investig
potenti
target
immunotherapi
correspond
tumor
much
remain
learn
mechan
host
immun
recognit
antibodi
respons
class
cryptic
glycoantigen
refer
web
version
pubm
central
supplementari
materi
project
describ
support
nation
cancer
institut
grant
number
content
sole
respons
author
necessarili
repres
offici
view
nation
cancer
institut
nation
institut
health
sera
subject
pca
bph
character
use
carbohydr
array
array
dataset
process
statist
analyz
use
sa
institut
jmp
genom
softwar
packag
result
present
overlay
plot
illustr
antibodi
profil
subject
enabl
visual
comparison
two
group
cancer
vs
bph
b
dot
plot
mean
valu
igg
score
triplic
array
detect
sampl
microarray
dataset
present
supplement
tabl
oneway
analysi
perform
compar
group
mean
among
select
autoantigen
list
panel
dot
panel
repres
mean
valu
igg
score
triplic
array
detect
subject
mean
shown
bar
standard
deviat
green
diamond
around
mean
valu
comparison
circl
student
ttest
appear
right
mean
diamond
illustr
signific
differ
among
mean
graphic
show
intersect
circl
allow
visual
inspect
signific
differ
circl
intersect
less
signific
differ
vice
versa
